Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

J.J.R. Grob, M.M. Amonkar, S. Martín-Algarra, L.V. Demidov, V.L. Goodman, K.M. Grotzinger, P. Haney, E. Kämpgen, B. Karaszewska, C. Mauch, J.H. Miller, Michael Millward, B. Mirakhur, P. Rutkowski, V. Chiarion Sileni, S. Swann, A. Hauschild

    Research output: Contribution to journalArticlepeer-review

    35 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine'. Together they form a unique fingerprint.

    Medicine & Life Sciences